Search
Multiple Sclerosis Paid Clinical Trials in Nebraska
A listing of 4 Multiple Sclerosis clinical trials in Nebraska actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 4 of 4
The state of Nebraska currently has 4 active clinical trials seeking participants for Multiple Sclerosis research studies. These trials are conducted in various cities, including Omaha, Lincoln, Kearney and Grand Island.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Acid Reflux Esophagus Damage Study
Recruiting
Sign up for a clinical trial today and contribute to the advancement of medical research, paving the way for innovative treatments. Receive financial compensation for your participation and benefit from complimentary medical care.
Featured Trial
Child/Teen Migraine Study
Recruiting
Join a clinical trial today and take a step toward finding a better solution for you. Earn money for your time and no-cost medical treatment is provided.
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
Recruiting
This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course. This study focuses on upper limit disability progression. This study will consist of the following phases: screening, double-blind treatment, follow-up 1 (FU1), an optional open-label extension (OLE), follow-up 2 (FU2), and B-cell monitoring (BCM).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
04/10/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Multiple Sclerosis, Primary Progressive
The MS-LINK™ Outcomes Study
Recruiting
The Multiple Sclerosis (MS) Leadership and Innovation Network (MS-LINK™) is comprised of networks working cooperatively to advance Multiple Sclerosis (MS) science and improve MS participant outcomes. In this study participants will be followed from the time of consent through the lifetime of the study (currently 3 years), unless the participant chooses to withdraw from the study. Collection of participant's medical history, including MS and treatment history, will be automated through extraction... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: University of Nebraska medical Center, Omaha, Nebraska
Conditions: Multiple Sclerosis
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability.
The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Multiple Sclerosis, Relapsing-Remitting
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
Recruiting
Primary Objective:
To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS)
Secondary Objectives:
To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety and tolerability of SAR442168 To evaluate population pharmacokinetics (PK) of SAR442168 in PPMS and its relations... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/16/2024
Locations: University Of Nebraska Site Number : 8400129, Omaha, Nebraska
Conditions: Primary Progressive Multiple Sclerosis
1 - 4 of 4